Ibrance

Ibrance is used with a type of hormone therapy called an aromatase inhibitor to treat advanced or metastatic, hormone receptor positive, HER2 negative breast cancer that has previously been treated with hormone therapy in women or men. Arimidex (chemical name: anastrozole), aromasin (chemical name: eximistin) and femara (chemical name: letrozole) are aromatase inhibitors.

Ibrans is also approved for use with Phoslodex hormone therapy (chemical name: fulvestrant) to treat modern or metastatic, hormone receptor positive, HER2-negative breast cancer that has progressed after treatment.

How Ibrance works

Cancer cells grow out of control. Like Kisqali (chemical name: ribociclib) and Verzenio (chemical name: abemaciclib), Ibrance is a 4/6 inhibitor of the cyclone-dependent kinase (CDK). CDK4 / 6 inhibitors work by interfering with cancer cells and preventing cancer cells from dividing and growing.

Is Ibrance right for you?

Ibrance may be prescribed for postmenopausal women or men with aromatase inhibitors including modern or metastatic, hormone receptor-positive, HER2 negative breast cancer that has not yet been treated with hormone therapy.

Ibrance can be used in combination with Phoslodex in women or men to treat advanced or metastatic, hormone receptor positive, HER2 negative breast cancer that is enhanced after treatment with hormone therapy.

Advanced breast cancer is cancer that has returned (reappeared) or has spread beyond the breast to the Chest wall. Metastatic breast cancer is advanced cancer that has spread to other parts of the body away from the breast, such as the bones or the liver.

Femara, Aromasin, and Arimidex are all aromatase inhibitors, a type of hormone therapy. Aromatase inhibitors stop the production of estrogen. Aromatase inhibitors work by inhibiting the aromatase enzyme, which converts androgens into small amounts of estrogen in the body. This means that less estrogen is available for the growth of hormone receptor positive breast cancer cells. All aromatase inhibitors are oral tablets.

Faslodex is an estrogen receptor down regulator (ERD), another type of hormone therapy. It blocks the effect of estrogen on breast tissue by sitting on the estrogen receptor in breast cells. we give Faslodex by intramuscular injection.

To determine if a cancer estrogen receptor is positive, most testing labs use a special staining process that causes hormone receptors to appear in tissue samples. We call it an immunohistochemical staining test or immunohistochemistry (IHC). Not all laboratories use the same method to analyze test results. There is no need to report the test in the same way. So you can look at one of the following in your pathology report.

What to expect when taking Ibrance

The recommended initial dose of Ibrance is 125 mg. When you take Ibrance with aromatase inhibitor, you take pills on a 28 day cycle

For 21 days, take Ibrance tablets and aromatase inhibitor with food at the same time every day.

Then take only aromatase inhibitor for 7 days.

As long as you benefit from the medication and there are no annoying side effects, you continue to take Ebrance with an aromatase inhibitor.

When taking Ibrance with Faslodex, complete a 28-day cycle

Take Ibrance at the same time every day for 21 days, with food, then stop taking Ibrance tablets for 7 days

Get one injection of Phoslodex every 2 weeks for the first three injections and then one injection every 4 weeks

It is important to know that women who are pregnant or planning to become pregnant should not take Ibrance. Doctors do not know if Burns will harm your newborn. It is important that you do not become pregnant while you are taking Ibrance and that you use effective contraception for at least 2 weeks after the last dose.

Female partners who may become pregnant should use birth control when they are taking Ibrance for at least 3 months after the last dose.

Also, women who are breastfeeding or planning to breastfeed should not take Ibrance. Together, you and your doctor will decide whether to take Ibrance or breastfeeding.

Ibrance side effects

The most common side effects of Ibrance are:

  • fatigue
  • mouth sores
  • anemia (low red blood cell count)
  • decreased appetite
  • hair thinning or loss
  • diarrhea
  • vomiting
  • nausea
  • weakness

 

Leave a Reply

Your email address will not be published. Required fields are marked *

You cannot copy content of this page